title: FDG-PET in early AD diagnosis.
abstract: FDG-PET is a valuable tool that will continue to aid in identifying AD in its prodromal and early dementia stages, distinguishing it from other causes of dementia, and tracking progression of the disease. As brain FDG-PET scans and well-trained readers of these scans are becoming more widely available to clinicians who are becoming more informed about the role FDG-PET can play in early AD diagnosis, its use is expected to increase.
authors: Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA 90095-7370, USA.
authors: Jessica
authors: J
authors: Chew
authors: Daniel H S
authors: DH
authors: Silverman
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D058070:Asymptomatic Diseases; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging*; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D018450:Disease Progression; D042241:Early Diagnosis; D004734:Energy Metabolism / Q000502:physiology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D011379:Prognosis
chemical_list: D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18